Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Advanced-stage ovarian clear cell carcinoma (OCCC) exhibits resistance to conventional platinum-based chemotherapy.
• Key genetic alterations in OCCC include mutations in ARID1A and PIK3CA.
• Identifying novel therapeutic targets is crucial for improving OCCC treatment outcomes.

Purpose of the Study:

• To identify previously unknown mutated kinases in OCCC patients.
• To investigate the druggability of downstream signaling pathways affected in OCCC.
• To evaluate potential therapeutic strategies for advanced-stage OCCC.

Main Methods:

• Sequencing of the human kinome and cancer-related genes in 124 OCCC patients.
• Analysis of copy-number alterations in OCCC tumors.
• Drug sensitivity testing of OCCC cell lines and patient-derived xenografts using targeted inhibitors.

Main Results:

• Several low-frequency, previously unannotated driver kinase mutations were identified in OCCC.
• The PI3K/AKT/mTOR, MAPK, and ERBB pathways, as well as DNA repair pathways, are frequently altered in OCCC.
• OCCC cell lines and xenografts demonstrated significant sensitivity to mTORC1/2 inhibition.

Conclusions:

• mTORC1/2 inhibition represents a promising therapeutic strategy for ovarian clear cell carcinoma.
• Targeting the mTORC1/2 pathway could overcome chemotherapy resistance in OCCC.
• Further clinical investigation of mTORC1/2 inhibitors in OCCC is warranted.